心得安联合不同方式单侧肾上腺切除术在4例armc5突变患者中的疗效

Fan Yu, Baowen Yu, Hongwen Zhou, He Wei, Hong-Qi Fan
{"title":"心得安联合不同方式单侧肾上腺切除术在4例armc5突变患者中的疗效","authors":"Fan Yu, Baowen Yu, Hongwen Zhou, He Wei, Hong-Qi Fan","doi":"10.1055/a-2559-9643","DOIUrl":null,"url":null,"abstract":"<p><p>Limited research has explored the efficacy of β-blockers in combination with unilateral total, subtotal, or partial adrenalectomy in ARMC5-mutated patients with primary bilateral macronodular adrenocortical hyperplasia (PBMAH). Additionally, there is no consensus on determining the optimal side for adrenal gland resection. To assess the clinical utility of three unilateral adrenalectomy (ULA) modalities-total, subtotal, and partial-combined with β-blocker treatment in patients with PBMAH and Cushing's syndrome (CS). This study was conducted at a single tertiary referral center involving a series of four patients with suspected CS. Diagnosis of PBMAH was confirmed through dexamethasone suppression testing, evaluation of ectopic receptor expression, and whole-exome sequencing. Three patients underwent unilateral total, subtotal, or partial adrenalectomy, respectively, while one patient declined surgery. All patients received β-blocker treatment. The median treatment duration among the four ARMC5-mutuated PBMAH patients was 30.5 months (range: 6-45 months). Two patients who underwent total or subtotal adrenalectomy on the side with more pronounced nodularity showed postoperative improvement in clinical CS signs, glycemic control, and hypertension. These two patients, along with another patient with bilateral diffuse (non-nodular) adrenal hyperplasia who declined surgery, showed further improvement in hypercortisolism and cortisol/adrenocorticotropic hormone (ACTH) ratio (CAR: plasma cortisol (nmol/L)/plasma ACTH (pg/ml), newly reported as a reliable parameter of cortisol secretory capacity in patients with adrenal CS) after propranolol treatment. The patient who underwent partial adrenalectomy on the side with less pronounced nodularity showed no significant improvement in hypercortisolism or CAR, and the response to propranolol was also unsatisfactory. All four cases harbored pathogenic variants in the ARMC gene, including two novel germline mutations.In ARMC5-mutuated patients with PBMAH, unilateral total adrenalectomy on the side with more pronounced nodularity appears to be an effective treatment option. Propranolol may be considered as an alternative or adjunctive therapy to ULA for managing hypercortisolism in those with ARMC5 mutations.</p>","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":"235-245"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy of Propranolol Combined with Different Modalities of Unilateral Adrenalectomy in a Case Series of 4 ARMC5-mutated Patients.\",\"authors\":\"Fan Yu, Baowen Yu, Hongwen Zhou, He Wei, Hong-Qi Fan\",\"doi\":\"10.1055/a-2559-9643\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Limited research has explored the efficacy of β-blockers in combination with unilateral total, subtotal, or partial adrenalectomy in ARMC5-mutated patients with primary bilateral macronodular adrenocortical hyperplasia (PBMAH). Additionally, there is no consensus on determining the optimal side for adrenal gland resection. To assess the clinical utility of three unilateral adrenalectomy (ULA) modalities-total, subtotal, and partial-combined with β-blocker treatment in patients with PBMAH and Cushing's syndrome (CS). This study was conducted at a single tertiary referral center involving a series of four patients with suspected CS. Diagnosis of PBMAH was confirmed through dexamethasone suppression testing, evaluation of ectopic receptor expression, and whole-exome sequencing. Three patients underwent unilateral total, subtotal, or partial adrenalectomy, respectively, while one patient declined surgery. All patients received β-blocker treatment. The median treatment duration among the four ARMC5-mutuated PBMAH patients was 30.5 months (range: 6-45 months). Two patients who underwent total or subtotal adrenalectomy on the side with more pronounced nodularity showed postoperative improvement in clinical CS signs, glycemic control, and hypertension. These two patients, along with another patient with bilateral diffuse (non-nodular) adrenal hyperplasia who declined surgery, showed further improvement in hypercortisolism and cortisol/adrenocorticotropic hormone (ACTH) ratio (CAR: plasma cortisol (nmol/L)/plasma ACTH (pg/ml), newly reported as a reliable parameter of cortisol secretory capacity in patients with adrenal CS) after propranolol treatment. The patient who underwent partial adrenalectomy on the side with less pronounced nodularity showed no significant improvement in hypercortisolism or CAR, and the response to propranolol was also unsatisfactory. All four cases harbored pathogenic variants in the ARMC gene, including two novel germline mutations.In ARMC5-mutuated patients with PBMAH, unilateral total adrenalectomy on the side with more pronounced nodularity appears to be an effective treatment option. Propranolol may be considered as an alternative or adjunctive therapy to ULA for managing hypercortisolism in those with ARMC5 mutations.</p>\",\"PeriodicalId\":94001,\"journal\":{\"name\":\"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association\",\"volume\":\" \",\"pages\":\"235-245\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/a-2559-9643\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-2559-9643","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/12 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

有限的研究探讨了β受体阻阻剂联合单侧肾上腺全、次或部分切除术治疗armc5突变的原发性双侧大结节性肾上腺皮质增生(PBMAH)患者的疗效。此外,在确定肾上腺切除术的最佳侧位方面没有达成共识。评估三种单侧肾上腺切除术(ULA)方式——全部、次全和部分联合β受体阻滞剂治疗PBMAH和库欣综合征(CS)患者的临床应用。本研究在单一三级转诊中心进行,涉及4例疑似CS患者。通过地塞米松抑制试验、异位受体表达评估和全外显子组测序确认PBMAH的诊断。3例患者分别行单侧肾上腺全切除、次全切除或部分切除,1例患者拒绝手术。所有患者均接受β受体阻滞剂治疗。4例armc5相关PBMAH患者的中位治疗持续时间为30.5个月(范围:6-45个月)。2例在结节性更明显的一侧行肾上腺全切除术或次全切除术的患者术后临床CS症状、血糖控制和高血压均有改善。这两名患者,以及另一名拒绝手术治疗的双侧弥漫性(非结节性)肾上腺增生患者,在心得安治疗后,高皮质醇症和皮质醇/促肾上腺皮质激素(ACTH)比值(CAR:血浆皮质醇(nmol/L)/血浆ACTH (pg/ml),新近报道为肾上腺CS患者皮质醇分泌能力的可靠参数)进一步改善。在结节性较不明显的一侧进行肾上腺部分切除术的患者在高皮质醇症或CAR方面没有明显改善,对心得安的反应也不令人满意。所有四个病例都携带ARMC基因的致病变异,包括两个新的种系突变。在armc5突变的PBMAH患者中,单侧肾上腺全切除结节性更明显的一侧似乎是一种有效的治疗选择。对于ARMC5突变患者,心得安可作为ULA治疗高皮质醇症的替代或辅助治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Efficacy of Propranolol Combined with Different Modalities of Unilateral Adrenalectomy in a Case Series of 4 ARMC5-mutated Patients.

Limited research has explored the efficacy of β-blockers in combination with unilateral total, subtotal, or partial adrenalectomy in ARMC5-mutated patients with primary bilateral macronodular adrenocortical hyperplasia (PBMAH). Additionally, there is no consensus on determining the optimal side for adrenal gland resection. To assess the clinical utility of three unilateral adrenalectomy (ULA) modalities-total, subtotal, and partial-combined with β-blocker treatment in patients with PBMAH and Cushing's syndrome (CS). This study was conducted at a single tertiary referral center involving a series of four patients with suspected CS. Diagnosis of PBMAH was confirmed through dexamethasone suppression testing, evaluation of ectopic receptor expression, and whole-exome sequencing. Three patients underwent unilateral total, subtotal, or partial adrenalectomy, respectively, while one patient declined surgery. All patients received β-blocker treatment. The median treatment duration among the four ARMC5-mutuated PBMAH patients was 30.5 months (range: 6-45 months). Two patients who underwent total or subtotal adrenalectomy on the side with more pronounced nodularity showed postoperative improvement in clinical CS signs, glycemic control, and hypertension. These two patients, along with another patient with bilateral diffuse (non-nodular) adrenal hyperplasia who declined surgery, showed further improvement in hypercortisolism and cortisol/adrenocorticotropic hormone (ACTH) ratio (CAR: plasma cortisol (nmol/L)/plasma ACTH (pg/ml), newly reported as a reliable parameter of cortisol secretory capacity in patients with adrenal CS) after propranolol treatment. The patient who underwent partial adrenalectomy on the side with less pronounced nodularity showed no significant improvement in hypercortisolism or CAR, and the response to propranolol was also unsatisfactory. All four cases harbored pathogenic variants in the ARMC gene, including two novel germline mutations.In ARMC5-mutuated patients with PBMAH, unilateral total adrenalectomy on the side with more pronounced nodularity appears to be an effective treatment option. Propranolol may be considered as an alternative or adjunctive therapy to ULA for managing hypercortisolism in those with ARMC5 mutations.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信